Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
ORIGINAL ARTICLES
Bacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection
Akira KawanoEiichi OgawaNorihiro FurusyoMakoto NakamutaEiji KajiwaraKazufumi DohmenHideyuki NomuraKazuhiro TakahashiTakeaki SatohKoichi AzumaYuichi TanabeShinji ShimodaKazuhiro KotohJun Hayashifor The Kyushu University Liver Disease Study (KULDS) Group
Author information
JOURNALS OPEN ACCESS

2015 Volume 54 Issue 6 Pages 567-572

Details
Abstract

Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and on-treatment predictors of bacterial infections in patients treated with TVR-based triple therapy.
Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria.
Results Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8%) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment.
Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.

Information related to the author
© 2015 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top